ArticleTranslational cancer research2025
Assessing mortality risk and causes in extramammary Paget's disease: insights from a population-based study.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The causes of death in extramammary Paget's disease (EMPD) patients are currently unclear. The authors aimed to examine mortality patterns among current survivors of EMPD. Methods: We conducted a retrospective cohort analysis utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database spanning from 2000 to 2019, focusing on patients diagnosed with EMPD. Standardized mortality ratios (SMRs) were employed to assess mortality rates in EMPD patients compared to the general population. Results: Our study comprised 1,002 patients diagnosed with EMPD, among whom 437 (43.6%) patients died during the follow-up period. In patients staged as localized, all malignant tumors accounted for 29.71% (n=101) of all deaths. Except for the 5-<10 years SMR being higher than the general population, no substantial difference was observed in SMR between EMPD and the general population for all causes of death. Among patients with regional/distant EMPD, 55 (56.70%) individuals died from all malignant tumors, while 42 (43.30%) individuals died from non-cancer causes. Throughout the follow-up period, the all-cause mortality rate was higher than that of the general population [SMR, 1.91; 95% confidence interval (CI): 1.55-2.33]. Cardiovascular and cerebrovascular diseases were the most common non-cancer causes of death in the whole cohort. Compared to patients aged 60-70 years and those aged 70 years and above, patients under 60 years had a lower SMR for all-cause mortality. Conclusions: Non-cancer related fatalities represent over 70% of cases in localized stage and 40% in regional/distant stage. Although the risk of all malignant tumors death is higher than that of the standard population, the overall risk of death for patients with localized stage is not increased. These data provide most up-to-date and comprehensive analysis of mortality causes among EMPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.